| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of merkel leptomeningeal evolution after complete remission upon anti–PD-1 treatment
|
Godeau, Marion
|
|
2019
|
113 |
C |
p. 55-57
|
artikel
|
| 2 |
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
|
Newton, C.
|
|
2019
|
113 |
C |
p. 19-27
|
artikel
|
| 3 |
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
|
McGowan, Daniel R.
|
|
2019
|
113 |
C |
p. 87-95
|
artikel
|
| 4 |
Cardiorespiratory fitness and site-specific risk of cancer in men: A systematic review and meta-analysis
|
Pozuelo-Carrascosa, D.P.
|
|
2019
|
113 |
C |
p. 58-68
|
artikel
|
| 5 |
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma
|
Kacew, Alec J.
|
|
2019
|
113 |
C |
p. 1-9
|
artikel
|
| 6 |
Combining conventional therapy with immunotherapy: A risky business?
|
Coosemans, A.
|
|
2019
|
113 |
C |
p. 41-44
|
artikel
|
| 7 |
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task
|
Brinker, Titus J.
|
|
2019
|
113 |
C |
p. 47-54
|
artikel
|
| 8 |
Establishing treatment optimisation as part of personalised medicine development
|
Lacombe, Denis
|
|
2019
|
113 |
C |
p. 96-97
|
artikel
|
| 9 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
|
Milano, Gérard
|
|
2019
|
113 |
C |
p. 45-46
|
artikel
|
| 10 |
Immune checkpoint inhibitor–associated hypophysitis—World Health Organisation VigiBase report analysis
|
Guerrero, Elisa
|
|
2019
|
113 |
C |
p. 10-13
|
artikel
|
| 11 |
Melanoma during fingolimod treatment for multiple sclerosis
|
Velter, C.
|
|
2019
|
113 |
C |
p. 75-77
|
artikel
|
| 12 |
Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study
|
Ham, Janneke C.
|
|
2019
|
113 |
C |
p. 32-40
|
artikel
|
| 13 |
Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis
|
Tedbirt, Billal
|
|
2019
|
113 |
C |
p. 72-74
|
artikel
|
| 14 |
Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
|
Katsuya, Yuki
|
|
2019
|
113 |
C |
p. 78-86
|
artikel
|
| 15 |
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
|
Bayle, Arnaud
|
|
2019
|
113 |
C |
p. 28-31
|
artikel
|
| 16 |
The successful treatment of metastatic androgen receptor–positive tumours of parotid origin with androgen receptor blockade and immunotherapy
|
Dalgleish, Angus G.
|
|
2019
|
113 |
C |
p. 14-18
|
artikel
|
| 17 |
Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib
|
Chen, Chia-Yu
|
|
2019
|
113 |
C |
p. 69-71
|
artikel
|
Tijdschrift beschrijving